CytoDyn color logo - no R.png
CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India
13 mai 2021 08h56 HE | CytoDyn Inc.
Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries VANCOUVER, Washington, May 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn”...
CytoDyn color logo - no R.png
CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9
07 mai 2021 06h00 HE | CytoDyn Inc.
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) --...
CytoDyn color logo - no R.png
CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials - a Small Trial in Critically Ill and a Large Trial in Severe Populations
05 mai 2021 03h35 HE | CytoDyn Inc.
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients VANCOUVER, Washington, May 05, 2021 (GLOBE...
CytoDyn color logo - no R.png
CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives
03 mai 2021 09h05 HE | CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn color logo - no R.png
Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA
03 mai 2021 09h02 HE | CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a...
CytoDyn color logo - no R.png
CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results
03 mai 2021 09h00 HE | CytoDyn Inc.
Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) --...
CytoDyn color logo - no R.png
CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28
27 avr. 2021 16h01 HE | CytoDyn Inc.
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140),...
CytoDyn color logo - no R.png
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants
22 avr. 2021 23h52 HE | CytoDyn Inc.
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage...
CytoDyn color logo - no R.png
CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review
19 avr. 2021 06h05 HE | CytoDyn Inc.
Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill...
CytoDyn color logo - no R.png
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
19 avr. 2021 06h00 HE | CytoDyn Inc.
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release VANCOUVER, Washington, April 19, 2021 (GLOBE...